A major pharmaceutical manufacturer has commissioned market research to understand the unique issues and concerns of those diagnosed CLL.
Your participation in this project will help to expand on new treatments, as well as enhance awareness and improve education about Blood Cancers.
To qualify, patients must have experience taking Intravenous immunoglobulin (IVIg) and or Subcutaneous immunoglobulin (SCIg).
Flince Research + Design, an independent healthcare research and consulting firm located in the U.S., has been engaged to conduct these research interviews on the pharmaceutical manufacturer’s behalf.
The research project consists of a 90-minute interview followed by the completion of a short journal.
You will not be asked to prepare for this interview in any way, and research will be conducted in strict accordance with all pertinent privacy laws and regulations.
Your participation will remain completely confidential.
In appreciation of your time and valuable contribution, you will receive an honorarium of $400 payable upon successful completion of the interview.
Research is open to U.S. residents only and participation is on a first-come, first-served basis.
For more information on how you may participate, please contact:
Jason Turner, Field Director
Flince Research + Design
+1 773 383 9090 [email protected]
